Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syros Pharmaceuticals, Inc. - Common Stock
(NQ:
SYRS
)
0.2000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
37,729
Open
0.2000
Bid (Size)
0.2026 (100)
Ask (Size)
0.2099 (50)
Prev. Close
0.2000
Today's Range
0.2000 - 0.2000
52wk Range
0.1830 - 8.170
Shares Outstanding
20,595,503
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 13, 2024
Via
Benzinga
S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results
November 13, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Performance
YTD
-97.45%
-97.45%
1 Month
-31.79%
-31.79%
3 Month
-89.36%
-89.36%
6 Month
-96.56%
-96.56%
1 Year
-97.14%
-97.14%
More News
Read More
Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings
November 13, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
November 13, 2024
Via
Benzinga
US Stocks Mixed; Inflation Rate Increases In October
November 13, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
November 13, 2024
Via
Benzinga
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
November 12, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
October 31, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
September 04, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
August 27, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
August 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
August 20, 2024
From
The Schall Law Firm
Via
Business Wire
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
August 13, 2024
Via
Benzinga
Exposures
Fossil Fuels
S&P 500 Gains 1%; Home Depot Earnings Top Views
August 13, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
August 13, 2024
Via
Benzinga
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
Via
Benzinga
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
August 13, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 13, 2024
Via
InvestorPlace
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
August 13, 2024
Via
Benzinga
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
August 12, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
July 31, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
July 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
June 13, 2024
From
Syros Pharmaceuticals
Via
Business Wire
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.